Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Christensen, Thomas Decker ; Vad, Henrik ; Pedersen, Søren ; Hornbech, Kåre ; Zois, Nora Elisabeth ; Licht, Peter B ; Nybo, Mads ; Hvas, Anne-Mette. / Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy : A randomized, controlled trial. I: P L o S One. 2017 ; Bind 12, Nr. 2. s. e0171809.

Bibtex

@article{c2173173af7c4e4c8db4dbbb753f97ff,
title = "Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial",
abstract = "BACKGROUND: Knowledge about the impact of Low-Molecular-Weight Heparin (LMWH) on the coagulation system in patients undergoing minimal invasive lung cancer surgery is sparse. The aim of this study was to assess the effect of LMWH on the coagulation system in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer.METHODS: Sixty-three patients diagnosed with primary lung cancer undergoing VATS lobectomy were randomized to either subcutaneous injection with dalteparin (Fragmin{\textregistered}) 5000 IE once daily or no intervention. Coagulation was assessed pre-, peri-, and the first two days postoperatively by standard coagulation blood test, thromboelastometry (ROTEM{\textregistered}) and thrombin generation.RESULTS: Patients undergoing potential curative surgery for lung cancer were not hypercoagulable preoperatively. There was no statistically significant difference in the majority of the assessed coagulation parameters after LMWH, except that the no intervention group had a higher peak thrombin and a shorter INTEM clotting time on the first postoperative day and a lower fibrinogen level on the second postoperative day. A lower level of fibrin d-dimer in the LMWH group was found on the 1. and 2.postoperative day, although not statistical significant. No differences were found between the two groups in the amount of bleeding or number of thromboembolic events.CONCLUSIONS: Use of LMWH administered once daily as thromboprophylaxis did not alter the coagulation profile per se. As the present study primarily evaluated biochemical endpoints, further studies using clinical endpoints are needed in regards of an optimized thromboprophylaxis approach.",
keywords = "Aged, Anticoagulants, Blood Coagulation, Female, Fibrin Fibrinogen Degradation Products, Fibrinogen, Heparin, Low-Molecular-Weight, Humans, Lung Neoplasms, Male, Middle Aged, Partial Thromboplastin Time, Postoperative Period, Thoracic Surgery, Video-Assisted, Thrombin, Thromboembolism, Journal Article, Randomized Controlled Trial",
author = "Christensen, {Thomas Decker} and Henrik Vad and S{\o}ren Pedersen and K{\aa}re Hornbech and Zois, {Nora Elisabeth} and Licht, {Peter B} and Mads Nybo and Anne-Mette Hvas",
year = "2017",
doi = "10.1371/journal.pone.0171809",
language = "English",
volume = "12",
pages = "e0171809",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy

T2 - A randomized, controlled trial

AU - Christensen, Thomas Decker

AU - Vad, Henrik

AU - Pedersen, Søren

AU - Hornbech, Kåre

AU - Zois, Nora Elisabeth

AU - Licht, Peter B

AU - Nybo, Mads

AU - Hvas, Anne-Mette

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Knowledge about the impact of Low-Molecular-Weight Heparin (LMWH) on the coagulation system in patients undergoing minimal invasive lung cancer surgery is sparse. The aim of this study was to assess the effect of LMWH on the coagulation system in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer.METHODS: Sixty-three patients diagnosed with primary lung cancer undergoing VATS lobectomy were randomized to either subcutaneous injection with dalteparin (Fragmin®) 5000 IE once daily or no intervention. Coagulation was assessed pre-, peri-, and the first two days postoperatively by standard coagulation blood test, thromboelastometry (ROTEM®) and thrombin generation.RESULTS: Patients undergoing potential curative surgery for lung cancer were not hypercoagulable preoperatively. There was no statistically significant difference in the majority of the assessed coagulation parameters after LMWH, except that the no intervention group had a higher peak thrombin and a shorter INTEM clotting time on the first postoperative day and a lower fibrinogen level on the second postoperative day. A lower level of fibrin d-dimer in the LMWH group was found on the 1. and 2.postoperative day, although not statistical significant. No differences were found between the two groups in the amount of bleeding or number of thromboembolic events.CONCLUSIONS: Use of LMWH administered once daily as thromboprophylaxis did not alter the coagulation profile per se. As the present study primarily evaluated biochemical endpoints, further studies using clinical endpoints are needed in regards of an optimized thromboprophylaxis approach.

AB - BACKGROUND: Knowledge about the impact of Low-Molecular-Weight Heparin (LMWH) on the coagulation system in patients undergoing minimal invasive lung cancer surgery is sparse. The aim of this study was to assess the effect of LMWH on the coagulation system in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer.METHODS: Sixty-three patients diagnosed with primary lung cancer undergoing VATS lobectomy were randomized to either subcutaneous injection with dalteparin (Fragmin®) 5000 IE once daily or no intervention. Coagulation was assessed pre-, peri-, and the first two days postoperatively by standard coagulation blood test, thromboelastometry (ROTEM®) and thrombin generation.RESULTS: Patients undergoing potential curative surgery for lung cancer were not hypercoagulable preoperatively. There was no statistically significant difference in the majority of the assessed coagulation parameters after LMWH, except that the no intervention group had a higher peak thrombin and a shorter INTEM clotting time on the first postoperative day and a lower fibrinogen level on the second postoperative day. A lower level of fibrin d-dimer in the LMWH group was found on the 1. and 2.postoperative day, although not statistical significant. No differences were found between the two groups in the amount of bleeding or number of thromboembolic events.CONCLUSIONS: Use of LMWH administered once daily as thromboprophylaxis did not alter the coagulation profile per se. As the present study primarily evaluated biochemical endpoints, further studies using clinical endpoints are needed in regards of an optimized thromboprophylaxis approach.

KW - Aged

KW - Anticoagulants

KW - Blood Coagulation

KW - Female

KW - Fibrin Fibrinogen Degradation Products

KW - Fibrinogen

KW - Heparin, Low-Molecular-Weight

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Partial Thromboplastin Time

KW - Postoperative Period

KW - Thoracic Surgery, Video-Assisted

KW - Thrombin

KW - Thromboembolism

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1371/journal.pone.0171809

DO - 10.1371/journal.pone.0171809

M3 - Journal article

C2 - 28199364

VL - 12

SP - e0171809

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

ER -

ID: 52044452